Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24633933 | 0.85 | — | — | |
| SCHEMBL2722431 | 0.81 | CA2 (0.39) | CA2BDKRB1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL20697783 | 0.80 | — | — | |
| SCHEMBL4330469 | 0.78 | FABP4 (0.39) | CA2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL7347312 | 0.76 | FABP4 (0.38) | CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL19083737 | 0.72 | FFAR3 (0.33) | ALDH1A1 | |
| SCHEMBL15114561 | 0.69 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL15219976 | 0.69 | — | — | |
| SCHEMBL30471330 | 0.67 | DGAT1 (0.38) | CA2BDKRB1ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL15482661 | 0.65 | SMN1; SMN2 (0.36) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2015-03-05 | — | — | US | claimed |
| EP-2668155-B1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-11-26 | — | — | EP | claimed |
| EP-2658848-A1 | NEW BIARYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | claimed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | claimed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | claimed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | claimed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-13 | — | — | US | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| EP-2668155-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-12-04 | — | — | EP | disclosed |
| US-8592426-B2 | Aryl-benzocycloalkyl amide derivatives | Hoffmann—La Roche Inc. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2658848-A1 | NEW BIARYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065516-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | CA2 4144/4885BDKRB1 549/4885ALDH1A1 974/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | CA2 2947/4885BDKRB1 3023/4885ALDH1A1 4844/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | CA2 2914/4885BDKRB1 3171/4885ALDH1A1 4331/4885 |
| US-20250051394-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | CA2 2914/4885BDKRB1 3171/4885ALDH1A1 4331/4885 |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | CA2 3827/4885BDKRB1 113/4885ALDH1A1 319/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | CA2 2914/4885BDKRB1 3171/4885ALDH1A1 4331/4885 |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | CA2 4144/4885BDKRB1 549/4885ALDH1A1 974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.